Bourla认为市场对Elrexfio仅6亿美元而竞品50亿美元的预测不合理,因其疗效相近且耐受性更好。
我再举Elrexfio的例子:市场预测竞品为50亿美元,而我们只有6亿美元。我们希望呈现疗效相近、耐受性和副作用更优的特征。原文 (en)
I will also mention another example of Elrexfio. Where for a competing product, the street is forecasting $5 billion, and for us $600 million. We aspire to present the profile that is very similar in efficacy and better in tolerability and in side effects.